Vasopeptidase inhibition - Solving the cardiovascular puzzle?

Drugs of the Future

Volumn 36, Issue 1, 2011, Pages 33-43

  Douglas, R G ^a   Ehlers, M R W ^b   Sturrock, Edward D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6,8,13 TETRAHYDRO 1,6,9,14 TETRAHYDROXY 3 (2 HYDROXYPROPYL) 7 METHOXY 8,13 DIOXOBENZO[A]NAPHTHACENE 2 CARBOXYLIC ACID; 7 (2 ACETYLTHIO 3 PHENYLPROPIONAMIDO) 1,2,3,4,6,7,8,12B OCTAHYDRO 6 OXOPYRIDO[2,1 A][2]BENZAZEPINE 4 CARBOXYLIC ACID; ALDOSTERONE; ALISKIREN; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; BOSENTAN; BRADYKININ; CARDIOVASCULAR AGENT; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN 1; FASIDOTRIL; GEMOPATRILAT; KININOGEN; LCZ 696; LISINOPRIL; LOSARTAN; OLMESARTAN; OMAPATRILAT; PREPROENDOTHELIN; RENIN; RXPA 380; SAMPATRILAT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VASOPEPTIDASE INHIBITOR;

ALDOSTERONE RELEASE; APPARENT MINERALOCORTICOID EXCESS SYNDROME; ARTERIAL PRESSURE; BLOOD PRESSURE; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; DRUG SAFETY; HEART FAILURE; HEART INFARCTION; HUMAN; KALLIKREIN KININ SYSTEM; KIDNEY DISEASE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM RETENTION; VASOCONSTRICTION; VASODILATATION;

EID: 84952986645     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2011.036.01.1537940     Document Type: Review

References (92)

1. Mathers, C.D., Loncar, D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006, 3(11): e442.
2. van Mourik, M.S., Cameron, A., Ewen, M., Laing, R.O. Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI data. BMC Cardiovasc Disord 2010, 10: 25.
3. Trogdon, J.G., Finkelstein, E.A., Nwaise, I.A., Tangka, F.K., Orenstein, D. The economic burden of chronic cardiovascular disease for major insurers. Health Promot Pract 2007, 8(3): 234-42.
4. Leal, J., Luengo-Fernandez, R., Gray, A., Petersen, S., Rayner, M. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006, 27(13): 1610-9.
5. Luengo-Fernandez, R., Leal, J., Gray, A., Petersen, S., Rayner, M. Cost of cardiovascular diseases in the United Kingdom. Heart 2006, 92(10): 1384-9.
6. Page, I.H., Helmer, O.M. A crystalline pressor substance (angiotonin) resulting from the interaction between renin and renin activator. J Exp Med 1940, 71(1): 29-42.
7. Skeggs, L.T., Marsh, W.H., Kahn, J.R., Shumway, N.P. The purification of hypertensin I. J Exp Med 1954, 100(4): 363-70.
8. Skeggs, L.T., Kahn, J.R., Shumway, N.P. The preparation and function of the hypertensin-converting enzyme. J Exp Med 1956, 103(3): 295-9.
9. Acharya, K.R., Sturrock, E.D., Riordan, J.F., Ehlers, M.R. ACE revisited: A new target for structure-based drug design. Nat Rev Drug Discov 2003, 2(11): 891-902.
10. Lemarie, C.A., Schiffrin, E.L. The angiotensin II type 2 receptor in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 2010, 11(1): 19-31.
11. Rice, G.I., Thomas, D.A., Grant, P.J., Turner, A.J., Hooper, N.M. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 2004, 383(Pt. 1): 45-51.
12. Roks, A.J., van Geel, P.P., Pinto, Y.M., Buikema, H., Henning, R.H., de Zeeuw, D., van Gilst, W.H. Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999, 34(2): 296-301.
13. Krege, J.H., John, S.W., Langenbach, L.L. et al. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 1995, 375(6527): 146-8.
14. Esther, C.R. Jr., Howard, T.E., Marino, E.M., Goddard, J.M., Capecchi, M.R., Bernstein, K.E. Mice lacking angiotensin-converting enzyme have low blood pressure, renal pathology, and reduced male fertility. Lab Invest 1996, 74(5): 953-65.
15. Yanai, K., Saito, T., Kakinuma, Y. et al. Renin-dependent cardiovascular functions and renin-independent blood-brain barrier functions revealed by renin-deficient mice. J Biol Chem 2000, 275(1): 5-8.
16. Itoh, Y., Yanagisawa, M., Ohkubo, S. et al. Cloning and sequence analysis of cDNA encoding the precursor of a human endothelium-derived vasoconstrictor peptide, endothelin: Identity of human and porcine endothelin. FEBS Lett 1988, 231(2): 440-4.
17. Denault, J.B., Claing, A., D'Orleans-Juste, P., Sawamura, T., Kido, T., Masaki, T., Leduc, R. Processing of proendothelin-1 by human furin convertase. FEBS Lett 1995, 362(3): 276-80.
18. Yanagisawa, M., Inoue, A., Ishikawa, T. et al. Primary structure, synthesis, and biological activity of rat endothelin, an endothelium-derived vasoconstrictor peptide. Proc Natl Acad Sci U S A 1988, 85(18): 6964-7.
19. Takahashi, M., Matsushita, Y, Iijima, Y., Tanzawa, K. Purification and characterization of endothetin-converting enzyme from rat lung. J Biol Chem 1993, 268(28): 21394-8.
20. Pollock, D.M., Divish, B.J., Milicic, I., Novosad, E.I., Burres, N.S., Opgenorth, T.J. In vivo characterization of a phosphoramidon-sensitive endothetin-converting enzyme in the rat. Eur J Pharmacol 1993, 231(3): 459-64.
21. Motte, S., McEntee, K., Naeije, R. Endothelin receptor antagonists. Pharmacol Ther 2006, 110(3): 386-414.
22. Kimura, S., Kasuya, Y., Sawamura, T. et al. Conversion of big endothelin-1 to 21-residue endothelin-1 is essential for expression of full vasoconstrictor activity: Structure-activity relationships of big endothelin-1. J Cardiovasc Pharmacol 1989, 13(Suppl. 5): S5-7.
23. Opgenorth, T.J., Wu-Wong, J.R., Shiosaki, K. Endothelin-converting enzymes. FASEB J 1992, 6(9): 2653-9.
24. Vijayaraghavan, J., Scicli, A.G., Carretero, O.A., Slaughter, C., Moomaw, C., Hersh, L.B. The hydrolysis of endothelins by neutral endopeptidase 24.11 (enkephalinase). J Biol Chem 1990, 265(24): 14150-5.
25. Kisanuki, Y.Y., Emoto, N., Ohuchi, T. et al. Low blood pressure in endothelial cell-specific endothelin 1 knockout mice. Hypertension 2010, 56(1): 121-8.
26. Pandey, K.N. Biology of natriuretic peptides and their receptors. Peptides 2005, 26(6): 901-32.
27. Erdos, E.G., Skidgel, R.A. Neutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormones. FASEB J 1989, 3(2): 145-51.
28. Kenny, A.J., Bourne, A., Ingram, J. Hydrolysis of human and pig brain natriuretic peptides, urodilatin, C-type natriuretic peptide and some C-receptor ligands by endopeptidase-24.11. Biochem J 1993, 291(Pt. 1): 83-8.
29. Kakoki, M., Smithies, O. The kallikrein-kinin system in health and in diseases of the kidney. Kidney Int 2009, 75(10): 1019-30.
30. Skidgel, R.A., Engelbrecht, S., Johnson, A.R., Erdos, E.G. Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984, 5(4): 769-76.
31. Skidgel, R.A., Alhenc-Gelas, F., Campbell, W.B. Prologue: Kinins and related systems. New life for old discoveries. Am J Physiol Heart Circ Physiol 2003, 284(6): H1886-91.
32. Hoang, M.V., Turner, A.J. Novel activity of endothelin-converting enzyme: Hydrolysis of bradykinin. Biochem J 1997, 327(Pt. 1): 23-6.
33. Pitt, B., Poole-Wilson, P.A., Segal, R. et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial-The Losartan Heart Failure Survival Study ELITE II. Lancet 2000, 355(9215): 1582-7.
34. Timmermans, P.B., Wong, R.C., Chiu, A.T. et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 1993, 45(2): 205-51.
35. Granger, C.B., McMurray, J.J., Yusuf, S. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet 2003, 362(9386): 772-7.
36. Dahlof, B., Devereux, R.B., Kjeldsen, S.E. et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002, 359(9311): 995-1003.
37. Yusuf, S., Teo, K.K., Pogue, J. et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008, 358(15): 1547-59.
38. Pfeffer, M.A., McMurray, J.J., Velazquez, E.J. et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349(20): 1893-906.
39. Cohn, J.N., Tognoni, G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345(23): 1667-75.
40. McMurray, J.J., Ostergren, J., Swedberg, K. et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet 2003, 362(9386): 767-71.
41. Messerli, F.H., Yuzefpolskaya, M. Q: Is an ACE inhibitor plus an ARB more effective than either drug alone? Cleve Clin J Med 2009, 76(12): 693-6.
42. Bomback, A.S., Toto, R. Dual blockade of the renin-angiotensin- aldosterone system: Beyond the ACE inhibitor and angiotensin-II receptor blocker combination. Am J Hypertens 2009, 22(10): 1032-40.
43. Sipahi, I., Debanne, S.M., Rowland, D.Y., Simon, D.I., Fang, J.C. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomised controlled trials. Lancet Oncol 2010, 11(7): 627-36.
44. Dusing, R., Sellers, F. ACE inhibitors, angiotensin receptor blockers and direct renin inhibitors in combination: A review of their role after the ONTARGET trial. Curr Med Res Opin 2009, 25(9): 2287-301.
45. Musini, V.M., Fortin, P.M., Bassett, K., Wright, J.M. Blood pressure lowering efficacy of renin inhibitors for primary hypertension: A Cochrane systematic review. J Hum Hypertens 2009, 23(8): 495-502.
46. Reudelhuber, T.L. Prorenin, renin, and their receptor: Moving targets. Hypertension 2010, 55(5): 1071-4.
47. Battistini, B., Berthiaume, N., Kelland, N.F., Webb, D.J., Kohan, D.E. Profile of past and current clinical trials involving endothelin receptor antagonists: The novel "-sentan" class of drug. Exp Biol Med (Maywood) 2006, 231(6): 653-95.
48. Emoto, N., Raharjo, S.B., Isaka, D., Masuda, S., Adiarto, S., Jeng, A.Y., Yokoyama, M. Dual ECE/NEP inhibition on cardiac and neurohumoral function during the transition from hypertrophy to heart failure in rats. Hypertension 2005, 45(6): 1145-52.
49. Weber, M.A., Black, H., Bakris, G. et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: A randomised, double-blind, placebo-controlled trial. Lancet 2009, 374(9699): 1423-31.
50. Wada, A., Tsutamoto, T., Ohnishi, M., Sawaki, M., Fukai, D., Maeda, Y., Kinoshita, M. Effects of a specific endothelin-converting enzyme inhibitor on cardiac, renal, and neurohumoral functions in congestive heart failure: Comparison of effects with those of endothelin A receptor antagonism. Circulation 1999, 99(4): 570-7.
51. Dickstein, K., De Voogd, H.J., Miric, M.P., Willenbrock, R., Mitrovic, V., Pacher, R., Koopman, P.A. Effect of single doses of SLV306, an inhibitor of both neutral endopeptidase and endothelin-converting enzyme, on pulmonary pressures in congestive heart failure. Am J Cardiol 2004, 94(2): 237-9.
52. Jandeleit-Dahm, K.A. Dual ACE/NEP inhibitors - More than playing the ACE card. J Hum Hypertens 2006, 20(7): 478-81.
53. Williams, B. Resistant hypertension: An unmet treatment need. Lancet 2009, 374(9699): 1396-8.
54. Mellin, V., Jeng, A.Y., Monteil, C., Renet, S., Henry, J.P., Thuillez, C., Mulder, P. Triple ACE-ECE-NEP inhibition in heart failure: A comparison with ACE and dual ECE-NEP inhibition. J Cardiovasc Pharmacol 2005, 46(3): 390-7.
55. Speirs, C., Wagniart, F., Poggi, L. Perindopril postmarketing surveillance: A 12 month study in 47,351 hypertensive patients. Br J Clin Pharmacol 1998, 46(1): 63-70.
56. Morimoto, T., Gandhi, T.K., Fiskio, J.M. et al. An evaluation of risk factors for adverse drug events associated with angiotensin-converting enzyme inhibitors. J Eval Clin Pract 2004, 10(4): 499-509.
57. Nussberger, J., Cugno, M., Amstutz, C., Cicardi, M., Pellacani, A., Agostoni, A. Plasma bradykinin in angio-oedema. Lancet 1998, 351(9117): 1693-7.
58. Adam, A., Cugno, M., Molinaro, G., Perez, M., Lepage, Y., Agostoni, A. Aminopeptidase P in individuals with a history of angio-oedema on ACE inhibitors. Lancet 2002, 359(9323): 2088-9.
59. Emanueli, C., Grady, E.F., Madeddu, P. et al. Acute ACE inhibition causes plasma extravasation in mice that is mediated by bradykinin and substance P. Hypertension 1998, 31(6): 1299-304.
60. Ondetti, M.A., Rubin, B., Cushman, D.W. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977, 196(4288): 441-4.
61. Wei, L., Alhenc-Gelas, F., Corvol, P., Clauser, E. The two homologous domains of human angiotensin I-converting enzyme are both cataiytically active. J Biol Chem 1991, 266(14): 9002-8.
62. Soubrier, F., Alhenc-Gelas, F., Hubert, C., Allegrini, J., John, M., Tregear, G., Corvol, P. Two putative active centers in human angiotensin I-converting enzyme revealed by molecular cloning. Proc Natl Acad Sci U S A 1988, 85(24): 9386-90.
63. Fuchs, S., Xiao, H.D., Cole, J.M. et al. Role of the N-terminal catalytic domain of angiotensin-converting enzyme investigated by targeted inactivation in mice. J Biol Chem 2004, 279(16): 15946-53.
64. Fuchs, S., Xiao, H.D., Hubert, C. et al. Angiotensin-converting enzyme C-terminal catalytic domain is the main site of angiotensin I cleavage in vivo. Hypertension 2008, 51(2): 267-74.
65. Wei, C.C., Hase, N., Inoue, Y. et al. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest 2010, 120(4): 1229-39.
66. Ehlers, M.R. Safety issues associated with the use of angiotensin-converting enzyme inhibitors. Expert Opin Drug Saf 2006, 5(6): 739-40.
67. Natesh, R., Schwager, S.L., Sturrock, E.D., Acharya, K.R. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003, 421(6922): 551-4.
68. Corradi, H.R., Schwager, S.L., Nchinda, A.T., Sturrock, E.D., Acharya, K.R. Crystal structure of the N domain of human somatic angiotensin I-converting enzyme provides a structural basis for domain-specific inhibitor design. J Mol Biol 2006, 357(3): 964-74.
69. Georgiadis, D., Beau, F., Czarny, B., Cotton, J., Yiotakis, A., Dive, V. Roles of the two active sites of somatic angiotensin-converting enzyme in the cleavage of angiotensin I and bradykinin: Insights from selective inhibitors. Circ Res 2003, 93(2): 148-54.
70. Georgiadis, D., Cuniasse, P., Cotton, J., Yiotakis, A., Dive, V. Structural determinants of RXPA380, a potent and highly selective inhibitor of the angiotensin-converting enzyme C-domain. Biochemistry 2004, 43(25): 8048-54.
71. Kroger, W.L., Douglas, R.G., O'Neill, H.G., Dive, V., Sturrock, E.D. Investigating the domain specificity of phosphinic inhibitors RXPA380 and RXP407 in angiotensin-converting enzyme. Biochemistry 2009, 48(35): 8405-12.
72. Nchinda, A.T., Chibale, K., Redelinghuys, P., Sturrock, E.D. Synthesis of novel keto-ACE analogues as domain-selective angiotensin I-converting enzyme inhibitors. Bioorg Med Chem Lett 2006, 16(17): 4612-5.
73. Nchinda, A.T., Chibale, K., Redelinghuys, P., Sturrock, E.D. Synthesis and molecular modeling of a lisinopril-tryptophan analogue inhibitor of angiotensin I-converting enzyme. Bioorg Med Chem Lett 2006, 16(17): 4616-9.
74. Tabrizchi, R. Dual ACE and neutral endopeptidase inhibitors: Novel therapy for patients with cardiovascular disorders. Drugs 2003, 63(20): 2185-202.
75. Gros, C., Noel, N., Souque, A. et al. Mixed inhibitors of angiotensin-converting enzyme (EC 3.4.15.1) and enkephalinase (EC 3.4.24.11): Rational design, properties, and potential cardiovascular applications of glycopril and alatriopril. Proc Natl Acad Sci U S A 1991, 88(10): 4210-14.
76. Llorens, C., Gacel, G., Swerts, J.P., Perdrisot, R., Fournie-Zaluski, M.C., Schwartz, J.C., Roques, B.P. Rational design of enkephalinase inhibitors: Substrate specificity of enkephalinase studied from inhibitory potency of various dipeptides. Biochem Biophys Res Commun 1980, 96(4): 1710-6.
77. Dimitropoulos, N., Papakyriakou, A., Dalkas, G.A., Sturrock, E.D., Spyroulias, G.A. A computational approach to the study of the binding mode of dual ACE/NEP inhibitors. J Chem Inf Model 2010, 50(3): 388-96.
78. Trippodo, N.C., Robl, J.A., Asaad, M.M., Fox, M., Panchal, B.C., Schaeffer, T.R. Effects of omapatrilat in low, normal, and high renin experimental hypertension. Am J Hypertens 1998, 11(3, Pt. 1): 363-72.
79. Kostis, J.B., Packer, M., Black, H.R., Schmieder, R., Henry, D., Levy, E. Omapatrilat and enalapril in patients with hypertension: The Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trial. Am J Hypertens 2004, 17(2): 103-11.
80. Morazzoni, G., Allievi, L., Branca, E. et al. In vitro and ex vivo characterization of Z13752A, a new dual-acting ACE/NEP inhibitor. Eur J Pharm Sci 1998, 6(Suppl. 1): Abst 139.
81. Morazzoni, G., Allievi, L., Pauselli, F., Pocchiari, F., Semeraro, C. Dual inhibition of ACE and NEP activities induced by i.v. and oral administration of Z13752A in spontaneously hypertensive rats. Eur J Pharm Sci 1998, 6(Suppl. 1): Abst 138.
82. Rastegar, M.A., Marchini, F., Morazzoni, G., Vegh, A., Papp, J.G., Parratt, J.R. The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin. Br J Pharmacol 2000, 129(4): 671-80.
83. Johnson, A.G., Pearce, G.L., Danoff, T.M. A randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy and safety of dual ACE/NEP inhibitor GW660511X in mild-to-moderate hypertensive patients. J Hum Hypertens 2006, 20(7): 496-503.
84. Dive, V., Chang, C.F., Yiotakis, A., Sturrock, E.D. Inhibition of zinc metallopeptidases in cardiovascular disease-From unity to trinity, or duality? Curr Pharm Des 2009, 15(31): 3606-21.
85. Jullien, N., Makritis, A., Georgiadis, D., Beau, F., Yiotakis, A., Dive, V. Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors. J Med Chem 2010, 53(1): 208-20.
86. Fink, C.A., Qiao, Y., Berry, C.J., Sakane, Y., Ghai, R.D., Trapani, A.J. New alpha-thiol dipeptide dual inhibitors of angiotensin-I converting enzyme and neutral endopeptidase EC 3.4.24.11. J Med Chem 1995, 38(26): 5023-30.
87. Daull, P., Benrezzak, O., Arsenault, D. et al. Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats. Am J Hypertens 2005, 18(12, Pt. 1): 1606-13.
88. Daull, P., Blouin, A., Belleville, K. et al. Triple VPI CGS 35601 reduces high blood pressure in low-renin, high-salt Dahl salt-sensitive rats. Exp Biol Med (Maywood) 2006, 231(6): 830-3.
89. Daull, P., Lepage, R., Benrezzak, O. et al. The first preclinical pharmacotoxicological safety assessment of CGS 35601, a triple vasopeptidase inhibitor, in chronically instrumented, conscious, and unrestrained spontaneously hypertensive rats. Drug Chem Toxicol 2006, 29(2): 183-202.
90. Daull, P., Jeng, A.Y., Battistini, B. Towards triple vasopeptidase inhibitors for the treatment of cardiovascular diseases. J Cardiovasc Pharmacol 2007, 50(3): 247-56.
91. Gu, J., Noe, A., Chandra, P. et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 2010, 50(4): 401-14.
92. Ruilope, L.M., Dukat, A., Bohm, M., Lacourciere, Y., Gong, J., Lefkowitz, M.P. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010, 375(9722): 1255-66.